The natural history of idiopathic pulmonary fibrosis (IPF) is not well defined and its clinical course is variable. We sought to investigate the survival and incidence of acute exacerbations (AEs) and their significant predictors in newly diagnosed patients. 70 patients newly diagnosed with IPF were prospectively followed for at least 3 yrs. Baseline evaluation included Medical Research Council dyspnoea score (MRCDS), 6-min walk test, pulmonary function tests, all of which were repeated at 6 months, and high-resolution computed tomography. A retrospective cohort of 68 patients was used for confirmation. Mean survival from the time of diagnosis was 30 months, with a 3-yr mortality of 46%. A Risk stratificatiOn ScorE (ROSE) based on MRCDS > 3, 6-min walking distance ≤ 72% predicted and composite physiologic index > 41 predicted 3-yr mortality with high specificity. 6-month progression of ROSE predicted rapid progression. 3-yr incidence of AE was 18.6%, mostly occurring in the first 18 months; risk factors for AE were concomitant emphysema and low diffusing coefficient of the lung for carbon monoxide. Results were confirmed in an independent cohort of patients. In newly diagnosed IPF, advanced disease at presentation, rapid progression and AEs are the determinants of 3-yr survival. The purpose of the multifactorial ROSE is to risk-stratify patients in order to predict survival and detect rapid disease progression.

Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study / Mura, Marco; Porretta, Maria A; Bargagli, Elena; Sergiacomi, Gianluigi; Zompatori, Maurizio; Sverzellati, Nicola; Taglieri, Amedeo; Mezzasalma, Fabrizio; Rottoli, Paola; Saltini, Cesare; Rogliani, Paola. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 40:(2012), pp. 101-109. [10.1183/09031936.00106011]

Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study.

SVERZELLATI, Nicola;
2012-01-01

Abstract

The natural history of idiopathic pulmonary fibrosis (IPF) is not well defined and its clinical course is variable. We sought to investigate the survival and incidence of acute exacerbations (AEs) and their significant predictors in newly diagnosed patients. 70 patients newly diagnosed with IPF were prospectively followed for at least 3 yrs. Baseline evaluation included Medical Research Council dyspnoea score (MRCDS), 6-min walk test, pulmonary function tests, all of which were repeated at 6 months, and high-resolution computed tomography. A retrospective cohort of 68 patients was used for confirmation. Mean survival from the time of diagnosis was 30 months, with a 3-yr mortality of 46%. A Risk stratificatiOn ScorE (ROSE) based on MRCDS > 3, 6-min walking distance ≤ 72% predicted and composite physiologic index > 41 predicted 3-yr mortality with high specificity. 6-month progression of ROSE predicted rapid progression. 3-yr incidence of AE was 18.6%, mostly occurring in the first 18 months; risk factors for AE were concomitant emphysema and low diffusing coefficient of the lung for carbon monoxide. Results were confirmed in an independent cohort of patients. In newly diagnosed IPF, advanced disease at presentation, rapid progression and AEs are the determinants of 3-yr survival. The purpose of the multifactorial ROSE is to risk-stratify patients in order to predict survival and detect rapid disease progression.
2012
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study / Mura, Marco; Porretta, Maria A; Bargagli, Elena; Sergiacomi, Gianluigi; Zompatori, Maurizio; Sverzellati, Nicola; Taglieri, Amedeo; Mezzasalma, Fabrizio; Rottoli, Paola; Saltini, Cesare; Rogliani, Paola. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 40:(2012), pp. 101-109. [10.1183/09031936.00106011]
File in questo prodotto:
File Dimensione Formato  
Predicting survival in newly diagnosed IPF ERJ 12.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 753.6 kB
Formato Adobe PDF
753.6 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2521456
Citazioni
  • ???jsp.display-item.citation.pmc??? 57
  • Scopus 178
  • ???jsp.display-item.citation.isi??? 157
social impact